Amedisys Inc (AMED) Releases Q3 Earnings Guidance
Amedisys Inc (NASDAQ:AMED) updated its third quarter earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.54-0.56 for the period, compared to the Thomson Reuters consensus estimate of $0.53. The company issued revenue guidance of ~$386 million, compared to the consensus revenue estimate of $385.46 million.
A number of analysts recently commented on the stock. Royal Bank Of Canada reiterated a hold rating on shares of Amedisys in a report on Monday. Jefferies Group LLC reiterated a buy rating and issued a $60.00 target price on shares of Amedisys in a report on Thursday, October 12th. SunTrust Banks, Inc. reiterated a buy rating and issued a $60.00 target price on shares of Amedisys in a report on Monday, October 9th. Robert W. Baird reiterated a hold rating and issued a $50.00 target price on shares of Amedisys in a report on Wednesday, October 4th. Finally, Oppenheimer Holdings, Inc. reiterated a buy rating and issued a $60.00 target price on shares of Amedisys in a report on Friday, September 15th. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $56.20.
Amedisys Inc (AMED) traded down 0.38% during midday trading on Tuesday, hitting $49.54. 322,283 shares of the stock were exchanged. Amedisys Inc has a one year low of $34.58 and a one year high of $65.91. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of 42.34 and a beta of 0.87. The company has a 50 day moving average price of $51.59 and a 200 day moving average price of $55.12.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.12. The business had revenue of $378.80 million for the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the company posted $0.42 EPS. Equities analysts anticipate that Amedisys Inc will post $2.21 EPS for the current year.
In other news, Director Bruce D. Perkins purchased 2,000 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The shares were acquired at an average cost of $46.60 per share, for a total transaction of $93,200.00. Following the transaction, the director now directly owns 15,825 shares of the company’s stock, valued at approximately $737,445. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David B. Pearce sold 1,000 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the sale, the insider now owns 10,488 shares in the company, valued at $524,400. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.
WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/24/amedisys-inc-amed-releases-q3-earnings-guidance.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.